Upgrade to SI Premium - Free Trial

Cognex Reports First Quarter 2022 Results

May 5, 2022 4:06 PM

NATICK, Mass.--(BUSINESS WIRE)-- Cognex Corporation (NASDAQ: CGNX) today reported financial results for the first quarter of 2022. Table 1 below shows selected financial data for Q1-22 compared with Q1-21 and Q4-21.

Table 1

(Dollars in thousands, except per share amounts)

Revenue

Net Income

Net Income
per Diluted
Share

Non-GAAP
Net Income
per Diluted
Share*

Quarterly Comparisons

Current quarter: Q1-22

$282,407

$67,333

$0.38

$0.42

Prior year’s quarter: Q1-21

$239,027

$69,848

$0.39

$0.36

Change: Q1-21 to Q1-22

18%

(4)%

(3)%

17%

Prior quarter: Q4-21

$244,065

$53,535

$0.30

$0.30

Change: Q4-21 to Q1-22

16%

26%

27%

40%

*Non-GAAP net income per diluted share excludes discrete tax adjustments. A reconciliation from GAAP to Non-GAAP is shown in Exhibit 2 of this news release.

“Overall, I am pleased with our first quarter results,” said Robert J. Willett, Chief Executive Officer of Cognex. “Revenue was the second highest of any quarter in our company’s 41-year history and operating margin was above our 30% long-term target. This solid start to the year was driven by the increasing adoption of machine vision technology and the hard work of Cognoids through difficult conditions around the world to support our customers, manage our supply chain, and continue our product development efforts.”

Mr. Willett continued, “While our Q1 results were good, we believe growth momentum is slowing. We are currently hearing from customers that automation projects are taking longer to deploy, and some are being delayed, because of supply chain challenges and staffing shortages.”

Details of the Quarter

Statement of Operations Highlights – First Quarter of 2022

Balance Sheet Highlights – April 3, 2022

Financial Outlook – Q2 2022

Non-GAAP Financial Measures

Analyst Conference Call and Simultaneous Webcast

About Cognex Corporation

Cognex Corporation designs, develops, manufactures, and markets a wide range of image-based products, all of which use artificial intelligence (AI) techniques that give them the human-like ability to make decisions on what they see. Cognex products include machine vision systems, machine vision sensors, and barcode readers that are used in factories and distribution centers around the world where they eliminate production and shipping errors.

Cognex is the world's leader in the machine vision industry, having shipped more than 3 million image-based products, representing over $9 billion in cumulative revenue, since the company's founding in 1981. Headquartered in Natick, Massachusetts, USA, Cognex has offices and distributors located throughout the Americas, Europe, and Asia. For details, visit Cognex online at www.cognex.com.

Certain statements made in this news release, which do not relate solely to historical matters, are forward-looking statements. These statements can be identified by use of the words “expects,” “anticipates,” “estimates,” “believes,” “projects,” “intends,” “plans,” “will,” “may,” “shall,” “could,” “should,” and similar words and other statements of a similar sense. These statements are based on our current estimates and expectations as to prospective events and circumstances, which may or may not be in our control and as to which there can be no firm assurances given. These forward-looking statements, which include statements regarding business and market trends, future financial performance and financial targets, the expected impact of the COVID-19 pandemic on our assets, business and results of operations, customer demand and order rates and timing of related revenue, managing supply shortages, delivery lead times, future product mix, research and development activities, sales and marketing activities, new product offerings and product development activities, capital expenditures, investments, liquidity, dividends and stock repurchases, strategic and growth plans, and estimated tax benefits and expenses and other tax matters, involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include: (1) the reliance on key suppliers to manufacture and deliver quality products; (2) the inability to obtain components for our products; (3) the failure to effectively manage product transitions or accurately forecast customer demand; (4) the inability to manage disruptions to our distribution centers; (5) the inability to design and manufacture high-quality products; (6) the impact, duration, and severity of the COVID-19 pandemic, including the availability and effectiveness of vaccines; (7) the loss of, or curtailment of purchases by, large customers in the logistics industry; (8) information security breaches; (9) the inability to protect our proprietary technology and intellectual property; (10) the inability to attract and retain skilled employees and maintain our unique corporate culture; (11) the technological obsolescence of current products and the inability to develop new products; (12) the failure to properly manage the distribution of products and services; (13) the impact of competitive pressures; (14) the challenges in integrating and achieving expected results from acquired businesses; (15) potential disruptions in our business systems; (16) potential impairment charges with respect to our investments or acquired intangible assets; (17) exposure to additional tax liabilities; (18) fluctuations in foreign currency exchange rates and the use of derivative instruments; (19) unfavorable global economic conditions, including high inflation rates; (20) business disruptions from natural or man-made disasters or public health issues; (21) economic, political, and other risks associated with international sales and operations, including the impact of the war in Ukraine; and (22) our involvement in time-consuming and costly litigation; and the other risks detailed in Cognex reports filed with the SEC, including its Form 10-K for the fiscal year ended December 31, 2021 and Form 10-Q for the fiscal quarter ended April 3, 2022. You should not place undue reliance upon any such forward-looking statements, which speak only as of the date made. Cognex disclaims any obligation to update forward-looking statements after the date of such statements.

Exhibit 1

COGNEX CORPORATION

Statements of Operations

(Unaudited)

Dollars in thousands, except per share amounts

Three-months Ended

Apr. 3, 2022

Dec. 31, 2021

Apr. 4, 2021

Revenue

$

282,407

$

244,065

$

239,027

Cost of revenue (1)

78,790

69,082

54,045

Gross margin

203,617

174,983

184,982

Percentage of revenue

72

%

72

%

77

%

Research, development, and engineering expenses (1)

36,054

35,489

34,105

Percentage of revenue

13

%

15

%

14

%

Selling, general, and administrative expenses (1)

80,835

82,974

72,424

Percentage of revenue

29

%

34

%

30

%

Operating income

86,728

56,520

78,453

Percentage of revenue

31

%

23

%

33

%

Foreign currency gain (loss)

(444

)

(37

)

(1,008

)

Investment and other income

1,420

1,464

1,386

Income before income tax expense

87,704

57,947

78,831

Income tax expense

20,371

4,412

8,983

Net income

$

67,333

$

53,535

$

69,848

Percentage of revenue

24

%

22

%

29

%

Net income per weighted-average common and common-equivalent share:

Basic

$

0.39

$

0.30

$

0.40

Diluted

$

0.38

$

0.30

$

0.39

Weighted-average common and common-equivalent shares outstanding:

Basic

174,146

176,123

176,288

Diluted

176,668

179,322

179,971

Cash dividends per common share

$

0.065

$

0.065

$

0.060

Cash and investments per common share

$

4.57

$

5.17

$

4.96

Book value per common share

$

7.82

$

8.15

$

7.68

(1) Amounts include stock-based compensation expense, as follows:

Cost of revenue

$

563

$

380

$

248

Research, development, and engineering

4,448

3,377

4,003

Selling, general, and administrative

10,045

6,664

7,758

Total stock-based compensation expense

$

15,056

$

10,421

$

12,009

Exhibit 2

COGNEX CORPORATION

Reconciliation of Selected Items from GAAP to Non-GAAP

(Unaudited)

Dollars in thousands, except per share amounts

Three-months Ended

Apr. 3, 2022

Dec. 31, 2021

Apr. 4, 2021

Discrete tax adjustments reconciliation

Income before income tax expense (GAAP)

$

87,704

$

57,947

$

78,831

Income tax expense (GAAP)

$

20,371

$

4,412

$

8,983

Effective tax rate (GAAP)

23

%

8

%

11

%

Discrete tax benefit (expense) related to stock-based compensation

(117

)

1,148

5,207

Discrete tax benefit (expense) related to tax return filings and other

(6,221

)

(1,173

)

Total discrete tax adjustments

$

(6,338

)

$

(25

)

$

5,207

Income tax expense (Non-GAAP)

$

14,033

$

4,387

$

14,190

Effective tax rate (Non-GAAP)

16

%

8

%

18

%

Net income (Non-GAAP)

$

73,671

$

53,560

$

64,641

Percentage of revenue (Non-GAAP)

26

%

22

%

27

%

Net income per diluted weighted-average common and common-equivalent share (GAAP)

$

0.38

$

0.30

$

0.39

Per share impact of discrete tax adjustments identified above

0.04

(0.03

)

Net income per diluted weighted-average common and common-equivalent share (Non-GAAP)

$

0.42

$

0.30

$

0.36

Diluted weighted-average common and common-equivalent shares outstanding (GAAP)

176,668

179,322

179,971

Exhibit 3

COGNEX CORPORATION

Balance Sheets

(Unaudited)

Dollars in thousands

Apr. 3, 2022

Dec. 31, 2021

Assets

Cash and investments

$

794,164

$

907,364

Accounts receivable

155,065

130,348

Inventories

136,660

113,102

Property, plant, and equipment

77,870

77,546

Operating lease assets

32,217

23,157

Goodwill and intangible assets

252,228

253,601

Deferred tax assets

412,333

418,570

Other assets

73,578

79,974

Total assets

$

1,934,115

$

2,003,662

Liabilities and Shareholders' Equity

Accounts payable and accrued expenses

$

107,855

$

136,483

Deferred revenue and customer deposits

54,455

35,743

Operating lease liabilities

34,530

25,581

Income taxes

83,585

66,517

Deferred tax liabilities

279,729

293,769

Other liabilities

15,216

15,476

Shareholders' equity

1,358,745

1,430,093

Total liabilities and shareholders' equity

$

1,934,115

$

2,003,662

Susan Conway

Investor Relations

+1 508-650-3353

[email protected]

Source: Cognex Corporation

Categories

Business Wire Press Releases

Next Articles